Provided is a levodopa prodrug that overcomes the problems attributed to the hemodynamics of levodopa, such as the development of side effects associated with a high administration frequency or frequent administration. (2S)-2-amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid or a salt or solvate thereof is a levodopa prodrug that imparts steady movement of levodopa through the blood when orally administered and is therefore useful as a preventive or therapeutic drug for the treatment of Parkinson's disease and/or Parkinsonism that overcomes the problems associated with levodopa pharmaceutical preparations.本發明係提供一種左旋多巴前驅藥物體，其係克服了因投藥次數多或頻繁投藥之副作用產生等起因於左旋多巴之血中動態的問題點者。(2S)-2-胺基-3-(3,4-雙((2-(苄醯氧基)-2-甲基丙醯基)氧基)苯基)丙酸、其鹽或其溶劑合物係左旋多巴的前驅藥物體，藉由經口投藥可提供平順的左旋多巴血中推移，因此可用作為已克服左旋多巴製劑之問題點的巴金森病及/或巴金森症候群預防及治療藥物。
